Results 271 to 280 of about 4,355,570 (357)
This study discovers that SIRT1, a hub gene involved in glucolipid metabolic conversion in colorectal carcinoma (CRC), stimulates CX3CL1 secretion in CRC cells by activating FOXO1. The CX3CL1‐CX3CR1 signaling promotes the differentiation of TCF7+ regulatory T cells (Tregs) into an enhanced immunosuppressive TNFRSF9+ Treg phenotype.
Ruiyang Zi+18 more
wiley +1 more source
Marked Protection by Moderate Hypothermia after Experimental Traumatic Brain Injury [PDF]
Guy L. Clifton+5 more
openalex +1 more source
Wenxiang Meng and colleagues delve into the molecular mechanisms underlying curcumin's modulation of RNA post‐transcriptional N (6)‐methyladenosine (m6A) modification. It is found that curcumin interacts with the Z1‐type protein tyrosine phosphatase receptor (PTPRZ1), maintaining its enzymatic activity and thus regulating the phosphorylation of the m6A‐
Ninan Zhang+9 more
wiley +1 more source
Enhanced expression of transforming growth factor β1 in the rat brain after a localized cerebral injury [PDF]
Ann Logan+4 more
openalex +1 more source
Lycium barbarum glycopeptide (LBGP), which is further extracted from Lycium barbarum polysaccharides, exhibits significant protective effects against neomycin‐induced hearing dysfunction including oxidative stress in cochlea and loss of key cells in cochlea.
Yunhao Wu+12 more
wiley +1 more source
AAV2.7m8 serotype combined with the gfaABC1D promoter targets infection of supporting cells (SCs). AAV2.7m8‐gfaABC1D‐Gjb2 administration to mice results in excessive immune responses. The combination of AAV2.7m8‐gfaABC1D‐Gjb2 with dexamethasone (DEX) shows a synergistic effect and enhances the gene therapy effect in a conditional Cx26 null mice model ...
Xiaohui Wang+8 more
wiley +1 more source
The contribution of brain injury to the overall injury severity of brain-injured patients
Daniel Fife, Janine Jagger
openalex +1 more source
In this study, saponin‐coated silica@gold nanocarriers responsive to NIR radiation is developed to enhance intratympanic drug delivery for cisplatin‐induced hearing loss (CIHL) treatment. The biocompatibility and oto‐protective properties are validated both in vitro and in vivo.
Rawand A. Mustafa+6 more
wiley +1 more source